<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:xmi="http://www.omg.org/XMI" xmlns:pos="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:cas="http:///uima/cas.ecore" xmlns:tweet="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos/tweet.ecore" xmlns:type8="http:///org/apache/uima/ruta/type.ecore" xmlns:morph="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/morph.ecore" xmlns:dependency="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/dependency.ecore" xmlns:type6="http:///de/tudarmstadt/ukp/dkpro/core/api/semantics/type.ecore" xmlns:type9="http:///org/apache/uima/trials/type.ecore" xmlns:noNamespace="http:///uima/noNamespace.ecore" xmlns:type="http:///de/tudarmstadt/ukp/dkpro/core/api/anomaly/type.ecore" xmlns:type7="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type.ecore" xmlns:type3="http:///de/tudarmstadt/ukp/dkpro/core/api/metadata/type.ecore" xmlns:type4="http:///de/tudarmstadt/ukp/dkpro/core/api/ner/type.ecore" xmlns:type5="http:///de/tudarmstadt/ukp/dkpro/core/api/segmentation/type.ecore" xmlns:type2="http:///de/tudarmstadt/ukp/dkpro/core/api/coref/type.ecore" xmlns:constituent="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/constituent.ecore" xmlns:chunk="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/chunk.ecore" xmi:version="2.0"><cas:NULL xmi:id="0"/><tcas:DocumentAnnotation xmi:id="2" sofa="1" begin="0" end="1427" language="x-unspecified"/><type9:OSMean xmi:id="3" sofa="1" begin="641" end="644"/><type9:OSMean xmi:id="4" sofa="1" begin="672" end="702"/><type9:PFSMean xmi:id="5" sofa="1" begin="720" end="723"/><type9:PFSMean xmi:id="6" sofa="1" begin="748" end="776"/><type9:ORR xmi:id="7" sofa="1" begin="795" end="800"/><type9:ORR xmi:id="8" sofa="1" begin="809" end="814"/><cas:Sofa xmi:id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: The second-line chemotherapeutic treatment for metastatic urothelial &#13;&#10;cancer (UC) after failure of cisplatin-based first-line therapy needs to be&#13;&#10;improved. Based on encouraging phase II data of gemcitabine and paclitaxel&#13;&#10;(Taxol) (GP), this trial was designed to compare a short-term (arm A) versus a&#13;&#10;prolonged (arm B) second-line combination chemotherapy of GP.&#13;&#10;PATIENTS AND METHODS: Of 102 randomized patients, 96 were eligible for analysis. &#13;&#10;Primary end point was overall survival (OS). Secondary end points were&#13;&#10;progression-free survival (PFS), objective response rates (ORR) and toxicity.&#13;&#10;RESULTS: Neither OS [arm A: 7.8 (95% CI: 4.2-11.4), arm B: 8.0 (95% CI: 4.9-11.1)&#13;&#10;months] and PFS [arm A: 4.0 (95% CI: 0-8.0), arm B: 3.1 (95% CI: 1.9-4.2) months]&#13;&#10;nor ORR (arm A: 37.5%, arm B: 41.5%) were significantly different. On prolonged&#13;&#10;treatment, more patients experienced severe anemia (arm A: 6.7% versus arm B:&#13;&#10;26.7% grade III/IV anemia; P = 0.011). In six patients, treatment was stopped&#13;&#10;during the first cycle due to disease progression or toxicity. Two patients died &#13;&#10;due to treatment-related toxic effects.&#13;&#10;CONCLUSION: Due to rapid tumor progression and toxicity at this dosage and&#13;&#10;schedule in a multicenter setting, it was not feasible to deliver a prolonged&#13;&#10;regimen. However, a high response rate of ~40% makes GP a promising second-line&#13;&#10;treatment option for patients with metastatic UC."/><cas:View sofa="1" members="2 3 4 5 6 7 8"/></xmi:XMI>